REFERENCE
Timmer-Bonte JNH, Adang EMM, Termeer E, Severens JL, Tjan-Heijnen VCG.Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. Journal of Clinical Oncology 26: 290-296, No. 2, 10 Jan 2008
Rights and permissions
About this article
Cite this article
Antibacterials best bet for Dutch febrile neutropenia prevention. Pharmacoecon. Outcomes News 545, 4 (2008). https://doi.org/10.2165/00151234-200805450-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805450-00010